We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Microfluidic Chip Method to Improve Sepsis Diagnosis, Progression Evaluation and Prognosis Monitoring

By HospiMedica International staff writers
Posted on 27 Sep 2024

Sepsis, a severe and life-threatening condition, results from an uncontrolled immune response that can lead to multi-organ failure. Given its high mortality rate and the limitations of current diagnostic and monitoring methods, there is an urgent need to develop better tools for evaluating and managing sepsis. A research team has now introduced a novel prognostic evaluation method for sepsis patients using a microfluidic concentration gradient chip.

In this study, conducted by researchers at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (Hefei, China), a microfluidic chip was employed to analyze the chemotactic migration behaviors of neutrophils and T lymphocytes in sepsis patients. The researchers observed significant differences in neutrophil migration parameters between sepsis patients and healthy controls, including gradient sensing time, migration distance, peak velocity, and the chemotactic index. From these findings, they developed a comprehensive evaluation index for neutrophil migration function, which showed a strong correlation with established markers of sepsis severity and commonly used biomarkers. These results were published in Talanta.


Image: The microfluidic chip analyzes the chemotactic migration behaviors of neutrophils in sepsis patients (Talanta, 2024; DOI: 10.1016/j.talanta.2024.126801)
Image: The microfluidic chip analyzes the chemotactic migration behaviors of neutrophils in sepsis patients (Talanta, 2024; DOI: 10.1016/j.talanta.2024.126801)

The research team also investigated T-cell migration in sepsis patients using the microfluidic platform. They found that sepsis patients had impaired T-cell migration and elevated NADH/NAD+ levels. Further experiments suggested that these elevated levels were caused by alterations in the plasma microenvironment, likely due to mitochondrial dysfunction. By administering the mitochondrial-targeted drug MitoQ, the researchers were able to reverse these abnormalities and restore T cell migration function, offering a potential therapeutic strategy for sepsis. Related findings were published in SHOCK.

These studies present a promising new approach for diagnosing sepsis, evaluating disease progression, and monitoring prognosis. The development of a comprehensive index and the potential use of mitochondrial-targeted therapies offer new theoretical insights and could significantly enhance sepsis management and improve patient outcomes.


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Plasma Thawing System
QuickThaw DH8
New
Respiratory Gas Humidifier
prisma VENT AQUA

Latest Critical Care News

Cutting-Edge Intelligent Medical Sutures Accelerate Wound Healing

Fluorescent Dye Reveals Biochemical Conversations Between Cartilage and Bone in Early Osteoarthritis

New Guideline Details Management of CVD Risk Before, During and After Noncardiac Surgery